Sosei reports strong early results for SD118
Japan's Sosei has reported strong results from two Phase I trials of its SD118, a compound in development for the treatment of neuropathic pain.
The studies were both double-blind, placebo-controlled and dose escalating and were designed to evaluate the safety, tolerability and pharmacokinetics of SD118 administered in an oral formulation. The compound is being jointly developed with Australia's NeuroDiscovery.
Chief executive Shinichi Tamura said: "I am delighted that SD118 demonstrated a good safety profile, especially considering the wide range of doses tested. This project is now ready to move into the next step of development."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze